Our study reveals that in EGFR-mutant NSCLC, a minor EGFR-low expressing tumor clone can be essential to the development of drug resistance over time by microenvironmental modifications potentiating the tumor regrowth. The gene discussed is EGFR; the disease is neoplasm.